IRIS
MENNA, PIERANTONIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.976
NA - Nord America 2.342
EU - Europa 879
SA - Sud America 221
Continente sconosciuto - Info sul continente non disponibili 111
AF - Africa 34
OC - Oceania 13
Totale 8.576
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 3.606
US - Stati Uniti d'America 2.210
CN - Cina 683
HK - Hong Kong 373
IT - Italia 369
BR - Brasile 135
GB - Regno Unito 133
FR - Francia 96
DE - Germania 92
VN - Vietnam 66
BD - Bangladesh 59
CA - Canada 54
CZ - Repubblica Ceca 54
IN - India 45
MX - Messico 44
FI - Finlandia 26
AR - Argentina 22
NL - Olanda 22
CO - Colombia 21
ID - Indonesia 18
PH - Filippine 18
EC - Ecuador 13
ZA - Sudafrica 13
AU - Australia 12
MY - Malesia 12
PL - Polonia 11
TR - Turchia 11
VE - Venezuela 11
ES - Italia 10
SA - Arabia Saudita 10
UA - Ucraina 10
JP - Giappone 9
PK - Pakistan 9
CR - Costa Rica 8
JM - Giamaica 8
PY - Paraguay 8
CL - Cile 7
EE - Estonia 7
RU - Federazione Russa 7
TW - Taiwan 7
BE - Belgio 6
IQ - Iraq 6
JO - Giordania 6
MD - Moldavia 6
AE - Emirati Arabi Uniti 5
NP - Nepal 5
PT - Portogallo 5
AL - Albania 4
GT - Guatemala 4
IE - Irlanda 4
TH - Thailandia 4
UZ - Uzbekistan 4
AT - Austria 3
GE - Georgia 3
HN - Honduras 3
KR - Corea 3
LT - Lituania 3
SE - Svezia 3
SV - El Salvador 3
TN - Tunisia 3
AO - Angola 2
BO - Bolivia 2
CI - Costa d'Avorio 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
EG - Egitto 2
IL - Israele 2
MA - Marocco 2
MM - Myanmar 2
NI - Nicaragua 2
PE - Perù 2
BA - Bosnia-Erzegovina 1
BF - Burkina Faso 1
BG - Bulgaria 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CV - Capo Verde 1
DM - Dominica 1
ET - Etiopia 1
GA - Gabon 1
KG - Kirghizistan 1
KH - Cambogia 1
KN - Saint Kitts e Nevis 1
KZ - Kazakistan 1
LB - Libano 1
LK - Sri Lanka 1
LV - Lettonia 1
LY - Libia 1
ME - Montenegro 1
MR - Mauritania 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
OM - Oman 1
PA - Panama 1
RO - Romania 1
RW - Ruanda 1
SC - Seychelles 1
SN - Senegal 1
SY - Repubblica araba siriana 1
Totale 8.463
Salva come PNG Salva come JPEG
Città #
San Jose 563
Singapore 409
Ashburn 394
Hong Kong 370
Rome 242
Beijing 210
Hefei 184
Council Bluffs 131
Boardman 107
Columbus 100
London 83
Lauterbourg 79
Dallas 68
Santa Clara 67
Shanghai 61
Munich 48
Los Angeles 44
Brno 35
Phoenix 31
Mexico City 26
New York 26
San Francisco 26
Ho Chi Minh City 22
Pune 20
Redmond 20
Amsterdam 18
São Paulo 18
Olomouc 17
Hanoi 15
Turku 14
Seattle 13
Washington 13
Guangzhou 12
Toronto 12
Chicago 11
Helsinki 11
Manchester 11
Brooklyn 10
Boston 9
Brasília 9
Montreal 9
Naples 9
Warsaw 9
Bogotá 8
Nuremberg 8
Orem 8
San José 8
Tokyo 8
Milan 7
Rio de Janeiro 7
Buffalo 6
Caracas 6
Kuala Lumpur 6
Melbourne 6
Amman 5
Atlanta 5
Campinas 5
Chennai 5
Frankfurt am Main 5
Guayaquil 5
Haiphong 5
Hangzhou 5
Johannesburg 5
Las Vegas 5
Palermo 5
Philadelphia 5
Riyadh 5
The Dalles 5
Ankara 4
Biên Hòa 4
Charlotte 4
Dhaka 4
Haikou 4
Manila 4
New Delhi 4
Paris 4
Piscataway 4
Taipei 4
Tashkent 4
Tirana 4
Wuhan 4
Alessandria 3
Buenos Aires 3
Canberra 3
Colombo 3
Columbia 3
Curitiba 3
Dublin 3
Florence 3
Genoa 3
Guatemala City 3
Hanover 3
Hyderabad 3
Istanbul 3
Jakarta 3
Karachi 3
Lancaster 3
Lumberton 3
Memphis 3
Miami 3
Totale 3.843
Salva come PNG Salva come JPEG
Nome #
Pharmacology of Ranolazine versus Common Cardiovascular Drugs in Patients with Early Diastolic Dysfunction Induced by Anthracyclines or Nonanthracycline Chemotherapeutics: A Phase 2b Minitrial 243
Cardiovascular safety of anti-TNF-alpha therapies: Facts and unsettled issues. 240
Doxorubicinolone formation and efflux : A salvage pathway against epirubicin accumulation in human heart 222
Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real Life 220
Altered iron regulatory protein activities in doxorubicin-treated cardiomyocytes : Distinct roles of reactive oxygen species and of the secondary alcohol metabolite doxorubicinol 212
Anthracyclines and Cardiotoxicity: Is CARP a Forgotten Biomarker? 211
Cancer drugs and QT prolongation: weighing risk against benefit 209
The endogenous lusitropic and chronotropic agent, B-type natriuretic peptide, limits cardiac troponin release in cancer patients with an early impairment of myocardial relaxation induced by anthracyclines 206
Minimal sampling colistin pharmacokinetics in critically ill patients 206
Beyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio-oncology 205
4’- Epidoxorubicin to reexplore anthracycline degradation in cardiomyocytes 205
Cardiovascular toxicity of antitumor drugs :Translating molecular mechanisms into clinical facts 200
Cardio-oncology in clinical studies and real life 191
Defective taxane stimulation of epirubicinol formation in the human heart: Insights into the cardiac tolerability of epirubicin-taxane chemotherapies 183
Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity 168
Anthracycline Cardiotoxicity 157
Pharmacology of cardio-oncology: chronotropic and lusitropic effects of B-type natriuretic peptide in cancer patients with early diastolic dysfunction induced by anthracycline or nonanthracycline chemotherapy 148
Anthracycline degradation in cardiomyocytes: a journey to oxidative survival 139
Anthracyclines 135
Early Diastolic Dysfunction after Cancer Chemotherapy: Primary Endpoint Results of a Multicenter Cardio-Oncology Study 131
Anthracycline metabolism and toxicity in human myocardyum: Comparisons between doxorubicin, epirubicin, and a novel disaccaride analogue with redeced formation and [4Fe-4S]-reactivity of its secondary alchol metabolite 129
Anthracycline Cardiotoxicity 117
Defective one or two electron reduction of the anticancer anthracycline epirubicin in human heart: Relative importance of vesicular sequestration and impaired efficiency of electron addition 114
An introduction to the metabolic determinants of anthracycline cardiotoxicity 110
Cardiotoxicity of antitumor drugs 108
Cardiotoxicity of targeted cancer drugs: concerns, “The cart before the horse,” and lessons from trastuzumab 107
CARDIAC ANTHRACYCLINE ACCUMULATION AND B-TYPE NATRIURETIC PEPTIDE TO DEFINE RISK AND PREDICTORS OF CANCER TREATMENT RELATED EARLY DIASTOLIC DYSFUNCTION 106
Anthracyclines: molecular advances and pharmacological developments in antitumor activity and cardiotoxicity 106
Low dose anthracycline and risk of heart failure in a pharmacokinetic model of human myocardium exposure: analog specificity and role of secondary alcohol metabolites 105
Advances in Bruton tyrosine kinase (Btk) inhibition are steered by Bruton tyrosine kinase phylogeny 103
Isavuconazole: case report and pharmacokinetic considerations 87
Anthracyclines, diastolic dysfunction and the road to heart failure in Cancer survivors: An untold story 81
Ibrutinib and Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia: focus on atrial fibrillation and ventricular tachyarrhythmias/sudden cardiac death 81
Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin 80
Modeling human myocardium exposure to doxorubicin defines the risk of heart failure from low-dose doxorubicin 77
Low level tumor necrosis factor-alpha protects cardiomyocytes against high level tumor necrosis factor-alpha: brief insight into a beneficial paradox 76
Telaprevir raises the plasma/whole blood ribavirin ratio: trying to come full circle on a dangerous relationship 76
Rethinking drugs from chemistry to therapeutic opportunities: Pixantrone beyond Anthracyclines. 74
Safety and tolerability of a novel oral nutritional supplement in healthy volunteers 72
Further analytical, pharmacokinetic, and clinical observations on low-dose ponatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia 71
Development and Validation of a UHPLC-MS/MS-Based Method to Quantify Cenobamate in Human Plasma Samples 69
Pharmacology of Cardio-Oncology 69
The concomitant management of cancer therapy and cardiac therapy 68
What is cardiotoxicity? 67
Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: Implications for cardiotoxicity of doxorubicin-taxane chemotherapies 66
Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis 66
In vitro modelling of the structure-activity determinants of anthracycline cardiotoxicity. 66
Predictors of early or delayed diastolic dysfunction after anthracycline-based or nonanthracycline chemotherapy: a pharmacological appraisal 66
From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction: A Translational Approach 65
Doxorubicin-Dependent Reduction of Ferrylmyoglobin and Inhibition of Lipid Peroxidation: Implications for Cardiotoxicity of Anticancer Anthracyclines 64
Doxorubicin irreversibly inactivates Iron Regulatory Proteins 1 and 2 in cardiomyocytes : Evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy 64
NEW TARGETED DRUGS FOR ACUTE MYELOID LEUKEMIA AND ANTIFUNGALS: PHARMACOKINETIC CHALLENGES AND OPPORTUNITIES 63
The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: Insight to explain the cardiac safety of pixantrone in doxorubicin treated patients 63
Posaconazole and midostaurin in patients with FLT3-mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study 62
Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium 62
Pharmacological Foundation of Cardio-Oncology 59
Modified colistin regimen for critically ill patients with acute renal impairment and continuous renal replacement therapy 57
Oxidative degradation of cardiotoxic anticancer anthracyclines to phthalic acids. Novel function or ferrylmyoglobin 57
Doxorubicin metabolism to toxic species in human myocardium: stimulation by paclitaxel and docetaxel but not BMS 184476 or BMS 188797 56
Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model I Amrubicin accumulates to a lower level than doxorubicin or epirubicin 53
Primary prevention strategies for anthracycline cardiotoxicity: a brief overview 53
Managing anthracycline-induced cardiotoxicity: beginning with the end in mind 51
Tumour necrosis factor alpha (TNFα)cardiomyocyte preconditioning: clues to explain anti-TNFα agents contraindication in severe heart failure 50
Quantitative Analysis of Cenobamate and Concomitant Anti-Seizure Medications in Human Plasma via Ultra-High Performance Liquid Chromatography–Tandem Mass Spectrometry 50
High Incidence of Invasive Fungal Diseases in Patients with FLT3-Mutated AML Treated with Midostaurin: Results of a Multicenter Observational SEIFEM Study 50
Doxorubicin degradation in cardiomyocytes 49
Impairment of myocardial contractility by anticancer anthracyclines: role of secondary alcohol metabolites and evidence of reduced toxicity by a novel disaccharide analogue 49
Matters of the heart: The case of TNF-alpha targeting drugs 49
MEN 10755 : A novel disaccharide anthracycline with a reduced level of formation and [4Fe-4S]-reactivity of toxic alcohol metabolite in human heart . 49
The novel anthracycline MEN 10755 is less cardiotoxic than doxorubicin or epirubicin due to reduced formation and aconitase-reactivity its secondary alcohol metabolite 49
The reality of pixantrone in real life 48
Role of secondary alcohol metabolites in anthracycline cardiotoxicity: from hypotheses to new drugs 47
The use of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients undergoing cytoreductive surgery (CS) for peritoneal carcinomatosis of ovarian origin 47
Molecular determinants of the reduced cardiotoxicity of epirubicin 47
Doxorubicin dependent reduction of hypervalent ferrylmyoglobin: One more evidence against the oxidative nature of doxorubicin-induced cardiotoxicity 46
MEN 10755: a novel disaccaride anthracycline with a reduced level of formation and [4Fe-4S]- reactivity of toxic alcohol metabolite in human myocardium 45
Tnf-alpha induced cardioprotection: effects on reactive oxygen species (ros) and apoptosis 45
Tumor necrosis factor alpha and cardiomyocytes: evidence for a self-protective preconditioning 44
Ferrylmyoglobin-dependent oxidative degradation of doxorubicin: a novel pathway of anthracycline metabolism and toxicity 44
Efficacy and safety of low dose ponatinib in a case of Ph-positive acute lymphoblastic leukaemia 43
Translating molecular mechanisms into clinical facts 43
Doxorubicin inhibits ferrylmyoglobin-dependent lipid peroxidation 43
Taxanes stimolate Doxorubicin conversion to its cardiotoxic secondary alcohol metabolite doxorubicinol: studies in human myocardium 43
Recommendations for the harmonization of reference intervals in the therapeutic monitoring of antiepileptic drugs/Indicazioni per l’armonizzazione degli intervalli di riferimento nel monitoraggio terapeutico di farmaci antiepilettici 42
Defective one or two electron reduction of the anticancer anthracycline epirubicin in human heart: relative importance of vesicular sequestration and impaired efficiency of electron addition J. Biol. Chem 42
Do you know pixantrone? 40
In ®Entresto we trust 40
Doxorubicin Cardiotoxicity and the Control of Iron Metabolism: Quinone-Dependent and Independent Mechanisms 40
Cenobamate modulates EEG cortical activity and connectivity in individuals with drug-resistant epilepsy: a pharmaco-EEG study 39
Pixantrone (PIX) Inhibition of Doxorubicinol (DOXOL) Formation in Human Myocardium: Implications for Cardiac Safety in Non-Hodgkin Lymphoma (NHL) Patients with Prior Anthracycline Treatment 39
Taxanes stimulate doxorubicin conversion to its cardiotoxic secondary alcohol metabolite : Studies in human myocardium. 39
Humans and Rodents: The Case of hOAT4 and mOat5 38
Increasing doxorubicin antitumor activity through COX-2 inhibition without increasing cardiotoxicity 38
Correction: Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN) 37
Adjudication of Adverse Cardiovascular Events in Patients with Chronic Lymphocytic Leukaemia Treated with Ibrutinib: Deaths in GLOW or Blowing in the Wind? 22
Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib 18
Pharmacogenetic testing in Italy: results of a nationwide survey by the Joint Working Group for the pharmacogenetics implementation in Italy 14
Indications for the harmonization of the therapeutic ranges for antifungal agents 11
Optimizing Treatment, Minimizing Risk: Therapeutic Drug Monitoring in Hematological Malignancies 9
Bruton tyrosine kinase inhibitors and cardiovascular adverse events 8
Totale 8.573
Salva come PNG Salva come JPEG
Categoria #
all - tutte 54.073
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 54.073
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022214 0 0 0 0 0 0 1 92 4 0 5 112
2022/202356 2 1 1 4 2 2 15 0 3 3 22 1
2023/2024333 6 35 11 15 37 146 1 16 2 8 4 52
2024/20254.043 102 36 123 15 45 77 40 21 250 263 1.446 1.625
2025/20262.976 336 204 131 250 139 94 923 205 219 257 106 112
2026/2027950 74 334 370 172 0 0 0 0 0 0 0 0
Totale 8.576